NLM Digital Collections

Search

Start Over Subjects Medicaid -- economics ✖Remove constraint Subjects: Medicaid -- economics Subjects Prescription Drugs -- economics ✖Remove constraint Subjects: Prescription Drugs -- economics Copyright Public domain ✖Remove constraint Copyright: Public domain

1. Prices for and spending on specialty drugs in Medicare Part D and Medicaid: an in-depth analysis

Author(s):
Anderson-Cook, Anna, author
Maeda, Jared, author
Nelson, Lyle, author
Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

2. Prices for and spending on specialty drugs in Medicare Part D and Medicaid

Publication:
[Washington, DC] : Congressional Budget Office, March 2019
Subject(s):
Health Expenditures -- statistics & numerical data
Health Expenditures -- trends
Medicaid -- economics
Medicare Part D -- economics
Prescription Drugs -- economics
Drug Costs
Economics, Pharmaceutical -- trends
Forecasting
Medicaid -- trends
Medicare Part D -- trends
Orphan Drug Production -- economics
Humans
United States

3. A comparison of brand-name drug prices among selected federal programs

Author(s):
Baker, Colin, author
Laughery, Scott, author
Patel, Yash, author
Publication:
[Washington, DC] : Congressional Budget Office, February 2021
Subject(s):
Drug Costs -- statistics & numerical data
Government Programs -- economics
Medicaid -- economics
Federal Government
Medicare Part D -- economics
Prescription Drugs -- economics
United States
United States. Department of Defense.
United States. Department of Veterans Affairs.

5. One percent of drugs with Medicaid reimbursement were not FDA-approved

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, May 2019
Subject(s):
Drug Approval
Insurance, Health, Reimbursement -- economics
Insurance, Health, Reimbursement -- statistics & numerical data
Medicaid -- economics
Medicaid -- statistics & numerical data
Economics, Pharmaceutical
Fraud -- prevention & control
Prescription Drugs -- economics
Humans
United States
United States. Food and Drug Administration.